{"DataElement":{"publicId":"7756058","version":"1","preferredName":"New Tumor Event Present After Initial Treatment Melanoma Indicator","preferredDefinition":"A response to indicate whether or not a newly discovered tumor was present after the initial treatment of a tumor composed of atypical, neoplastic melanocytes.","longName":"6848796v1.0:7755594v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"6848796","version":"1","preferredName":"New Tumor Event Present After Initial Treatment","preferredDefinition":"Data pertinent to a newly discovered tumor._A question about whether a new tumor was present after the initial treatment.","longName":"6848792v1.0:6848794v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"6848792","version":"1","preferredName":"New Tumor Event Information","preferredDefinition":"Data pertinent to a newly discovered tumor.","longName":"C156810","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New Tumor Event Information","conceptCode":"C156810","definition":"Data pertinent to a newly discovered tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FEB9F25-D36F-4669-E053-F662850A1252","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"ONEDATA","dateModified":"2019-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6848794","version":"1","preferredName":"Was a New Tumor Event Present After Initial Treatment","preferredDefinition":"A question about whether a new tumor was present after the initial treatment.","longName":"C159899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Was a New Tumor Event Present After Initial Treatment","conceptCode":"C159899","definition":"A question about whether a new tumor was present after the initial treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FEB9F25-D380-4669-E053-F662850A1252","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"ONEDATA","dateModified":"2019-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEB9F25-D391-4669-E053-F662850A1252","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeDescription":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified 11/23/19 jk revised LN to use concept synonyms; removed dup terms. .  8-12-19 tt created for F/U form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7755594","version":"1","preferredName":"Melanoma New Tumor Event Indicator","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._A question about whether a new tumor was present after the initial treatment._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"7755594v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C89A534C-F748-523B-E053-4EBD850AB492","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"ONEDATA","dateModified":"2021-08-02","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C89A534C-F752-523B-E053-4EBD850AB492","beginDate":"2019-08-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"ONEDATA","dateModified":"2021-08-02","deletedIndicator":"No"},{"value":"Unknown: Could not be determined or unsure","valueDescription":"Indeterminate or Unknown","ValueMeaning":{"publicId":"6841632","version":"1","preferredName":"Indeterminate or Unknown","longName":"6841632","preferredDefinition":"An indication that something is indeterminate or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate or Unknown","conceptCode":"C157157","definition":"An indication that something is indeterminate or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C86-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C89A534C-F75C-523B-E053-4EBD850AB492","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"ONEDATA","dateModified":"2021-08-02","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"5682957","version":"1","preferredName":"Yes","longName":"5682957","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4DAE-2A6B-7561-E053-F662850A0EBD","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C89A534C-F766-523B-E053-4EBD850AB492","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"ONEDATA","dateModified":"2021-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7755593","version":"1","preferredName":"Melanoma Was a New Tumor Event Present After Initial Treatment Indicator","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:A question about whether a new tumor was present after the initial treatment.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C3224:C159899:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Was a New Tumor Event Present After Initial Treatment","conceptCode":"C159899","definition":"A question about whether a new tumor was present after the initial treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C89A534C-F71F-523B-E053-4EBD850AB492","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"ONEDATA","dateModified":"2021-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C89A534C-F730-523B-E053-4EBD850AB492","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeDescription":"8/2/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634325","version":"1","longName":"CM Follow Up","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"New Tumor Event After Initial","type":"Preferred Question Text","description":"New Tumor Event After Initial Treatment?","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C89CF139-7623-5AB8-E053-4EBD850A542C","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeDescription":"8/2/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}